Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Lorenzo Pelizza, Emanuela Leuci, Davide Maestri, Emanuela Quattrone, Silvia Azzali, Giuseppina Paulillo & Pietro Pellegrini. (2022) Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up. Nordic Journal of Psychiatry 76:7, pages 530-538.
Read now
Read now
Paweł Wójciak, Klaudia Domowicz, Marta Andrzejewska & Janusz K. Rybakowski. (2021) Negative symptoms in schizophrenia, assessed by the brief negative symptom scale, self-evaluation of negative symptom scale, and social cognition: a gender effect. International Journal of Psychiatry in Clinical Practice 25:3, pages 252-257.
Read now
Read now
Sven Ulrich & Thomas Messer. (2021) Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence. Current Medical Research and Opinion 37:7, pages 1233-1248.
Read now
Read now
Christoph U Correll & Nina R Schooler. (2020) Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Disease and Treatment 16, pages 519-534.
Read now
Read now
L. García-Álvarez, M. P. García-Portilla, J. R. Caso, L. de la Fuente-Tomás, L. González-Blanco, P. Sáiz Martínez, J. C. Leza & J. Bobes. (2019) Early versus late stage schizophrenia. What markers make the difference?. The World Journal of Biological Psychiatry 20:2, pages 159-165.
Read now
Read now
Luisa-Sophie Köster, Maren Carbon & Christoph U Correll. (2014) Emerging drugs for schizophrenia: an update. Expert Opinion on Emerging Drugs 19:4, pages 511-531.
Read now
Read now
Reji Thomas, Glen Baker, Serdar Dursun, Kathryn Todd, Kamaldeep Dhami, James Chue & Pierre Chue. (2014) Glycine Reuptake Inhibitors in the Treatment of Negative Symptoms of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 24:3, pages 195-200.
Read now
Read now
Articles from other publishers (53)
Alma Džubur Kulenović, Eldina Smajic Mešević, Emina Ribić, Selman Repišti, Tamara Radojičić & Nikolina Jovanović. (2021) Factor structure and internal consistency of the Clinical Assessment Interview for Negative Symptoms (CAINS) on a sample of persons with psychotic disorders in Bosnia and Herzegovina. Journal of Neural Transmission 129:7, pages 905-911.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S2-S13.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S1-S13.
Crossref
Crossref
Waldemar Kryszkowski & Tomasz Boczek. (2021) The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment—A Narrative Review. Journal of Clinical Medicine 10:7, pages 1475.
Crossref
Crossref
Thammanard Charernboon. (2022) Interplay among positive and negative symptoms, neurocognition, social cognition, and functioning in clinically stable patients with schizophrenia: a network analysis. F1000Research 10, pages 1258.
Crossref
Crossref
Thammanard Charernboon. (2022) Interplay among positive and negative symptoms, neurocognition, social cognition, and functioning in clinically stable patients with schizophrenia: a network analysis. F1000Research 10, pages 1258.
Crossref
Crossref
Thammanard Charernboon. (2021) Interplay among positive and negative symptoms, neurocognition, social cognition, and functional outcome in clinically stable patients with schizophrenia: a network analysis. F1000Research 10, pages 1258.
Crossref
Crossref
Areoo Samaei, Kamyar Moradi, Sayna Bagheri, Amir Ashraf-Ganjouei, Rosa Alikhani, Seiedeh Bentolhoda Mousavi, Farzin Rezaei & Shahin Akhondzadeh. (2020) Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. International Journal of Neuropsychopharmacology 23:12, pages 775-782.
Crossref
Crossref
Pedro R. Olivetti, Peter D. Balsam, Eleanor H. Simpson & Christoph Kellendonk. (2019) Emerging roles of striatal dopamine D2 receptors in motivated behaviour: Implications for psychiatric disorders. Basic & Clinical Pharmacology & Toxicology 126:S6, pages 47-55.
Crossref
Crossref
Ehsan Moazen-Zadeh, Samaneh Bayanati, Kimia Ziafat, Farzin Rezaei, Bita Mesgarpour & Shahin Akhondzadeh. (2020) Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology 34:5, pages 506-513.
Crossref
Crossref
Jana Lotter, Marisa Möller, Olivia Dean, Michael Berk & Brian H. Harvey. (2020) Studies on Haloperidol and Adjunctive α-Mangostin or Raw Garcinia mangostana Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats. Frontiers in Psychiatry 11.
Crossref
Crossref
Philip D. Harvey, Hiroshi Nakamura & Sadanori Miura. (2019) Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study. Neuropsychopharmacology Reports 40:1, pages 63-72.
Crossref
Crossref
Aikaterini Rammou, Helen L. Fisher, Sonia Johnson, Barnaby Major, Nikola Rahaman, Nick Chamberlain‐Kent & James M. Stone. (2017) Negative symptoms in first‐episode psychosis: Clinical correlates and 1‐year follow‐up outcomes in London Early Intervention Services. Early Intervention in Psychiatry 13:3, pages 443-452.
Crossref
Crossref
Mei San Ang, Gurpreet Rekhi & Jimmy Lee. (2019) Validation of the Brief Negative Symptom Scale and its association with functioning. Schizophrenia Research 208, pages 97-104.
Crossref
Crossref
Bertalan Németh, Rita Bendes, Balázs Nagy, Árpád Götze, Kristóf Kóczián, Margit Horváth, Izabella Deák, Bernadett Tóth & Zoltán Kaló. (2019) Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. Health Policy and Technology 8:1, pages 84-91.
Crossref
Crossref
Yong-ming Wang, Lai-quan Zou, Wen-lan Xie, Zhuo-ya Yang, Xiong-zhao Zhu, Eric F C Cheung, Thomas Alrik Sørensen, Arne Møller & Raymond C K Chan. (2019) Altered Functional Connectivity of the Default Mode Network in Patients With Schizo-obsessive Comorbidity: A Comparison Between Schizophrenia and Obsessive-compulsive Disorder. Schizophrenia Bulletin 45:1, pages 199-210.
Crossref
Crossref
Michael S. Ritsner, Herman Farkash, Boris Rauchberger, Avi Amrami-Weizman & Xavier Y. Zendjidjian. (2018) Assessment of health needs, satisfaction with care, and quality of life in compulsorily admitted patients with severe mental disorders. Psychiatry Research 267, pages 541-550.
Crossref
Crossref
Josep Maria Haro, Carlo Altamura, Ricardo Corral, Helio Elkis, Jonathan Evans, Marie-Odile Krebs, Mathias Zink, Ashok Malla, José Ignacio Méndez, Corrado Bernasconi, Justine Lalonde & Anna-Lena Nordstroem. (2018) Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study. Psychiatry Research 267, pages 56-62.
Crossref
Crossref
Lulu Zhang, Hongbo Zheng, Rengrong Wu, Furong Zhu, Thomas R. Kosten, Xiang-Yang Zhang & Jingping Zhao. (2018) Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry 85, pages 69-76.
Crossref
Crossref
Alireza Ghajar, Faezeh Gholamian, Maryam Tabatabei-Motlagh, Mohsen Afarideh, Farzin Rezaei, Maryam Ghazizadeh-Hashemi & Shahin Akhondzadeh. (2018) Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Human Psychopharmacology: Clinical and Experimental 33:4, pages e2662.
Crossref
Crossref
Peter Piper. (2018) Potential Safety Issues Surrounding the Use of Benzoate Preservatives. Beverages 4:2, pages 33.
Crossref
Crossref
Alireza Ghajar, Mohammad-Reza Khoaie-Ardakani, Zahara Shahmoradi, Amir-Reza Alavi, Mohsen Afarideh, Mohammad-Reza Shalbafan, Maryam Ghazizadeh-Hashemi & Shahin Akhondzadeh. (2018) L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research 262, pages 94-101.
Crossref
Crossref
Ying Li, Wen-xiu Li, Dong-jie Xie, Yi Wang, Eric F.C. Cheung & Raymond C.K. Chan. (2018) Grey matter reduction in the caudate nucleus in patients with persistent negative symptoms: An ALE meta-analysis. Schizophrenia Research 192, pages 9-15.
Crossref
Crossref
Bertalan Németh, Anett Molnár, Ron Akehurst, Margit Horváth, Kristóf Kóczián, György Németh, Árpád Götze & Zoltán Vokó. (2017) Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. Journal of Comparative Effectiveness Research 6:8, pages 639-648.
Crossref
Crossref
Gisela Mezquida, Bibiana Cabrera, Miquel Bioque, Silvia Amoretti, Antonio Lobo, Ana González-Pinto, Ana Espliego, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Daniel Bergé, Maria J. Escartí, Ángela Ibañez, Rafael Penadés, Ana M. Sánchez-Torres, Miguel Bernardo, Ana Meseguer, Emilio Fernandez-Egea, Jorge Vidal, Mara Parellada, Anna Alonso, Mireia Rabella, Patricia Vega, Amaia Ugarte, Helena Andrés-Bergareche, Fabiola Modrego, Julio Sanjuan, Eduardo J. Aguilar, Antoni Bulbena, Anna Mané, Marina Garriga, Ivette Morilla, Immaculada Baeza, Elena de la Serna, Fernando Contreras, Auria Albacete, Julio Bobes, M. Paz García-Portilla, Miguel Gutiérrez, Rafael Segarra, Isabel Morales-Muñoz, Roberto Rodriguez-Jimenez, Anna Butjosa, Judith Usall, Salvador Sarró, Ramón Landin-Romero, Jerónimo Saiz & Vicent Balanzá-Martínez. (2017) The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research 189, pages 84-90.
Crossref
Crossref
Joseph D. Piper & Peter W. Piper. (2017) Benzoate and Sorbate Salts: A Systematic Review of the Potential Hazards of These Invaluable Preservatives and the Expanding Spectrum of Clinical Uses for Sodium Benzoate. Comprehensive Reviews in Food Science and Food Safety 16:5, pages 868-880.
Crossref
Crossref
Simon Chiu. (2017) Exploring Standardized Zembrin® Extracts from the South African plant Sceletium tortuosum in Dual Targeting Phosphodiesterase-4 (PDE-4) and Serotonin Reuptake Inhibition as potential treatment in Schizophrenia. International Journal of Complementary & Alternative Medicine 6:5.
Crossref
Crossref
Anna-Lena Nordstroem, Darren Talbot, Corrado Bernasconi, Carmen Galani Berardo & Justine Lalonde. (2017) Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study. International Journal of Social Psychiatry 63:2, pages 139-150.
Crossref
Crossref
L. Bacconi & F. Gressier. (2017) Efficacité et tolérance des IPDE-5 dans le traitement de la dysfonction érectile chez le patient schizophrène : une revue de la littérature. L'Encéphale 43:1, pages 55-61.
Crossref
Crossref
Benedicto Crespo-Facorro, Miguel Bernardo, Josep Maria Argimon, Manuel Arrojo, Maria Fe Bravo-Ortiz, Ana Cabrera-Cifuentes, Julián Carretero-Román, Manuel A. Franco-Martín, Paz García-Portilla, Josep Maria Haro, José Manuel Olivares, Rafael Penadés, Javier del Pino-Montes, Julio Sanjuán & Celso Arango. (2017) Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. Revista de Psiquiatría y Salud Mental (English Edition) 10:1, pages 4-20.
Crossref
Crossref
Benedicto Crespo-Facorro, Miguel Bernardo, Josep Maria Argimon, Manuel Arrojo, Maria Fe Bravo-Ortiz, Ana Cabrera-Cifuentes, Julián Carretero-Román, Manuel A. Franco-Martín, Paz García-Portilla, Josep Maria Haro, José Manuel Olivares, Rafael Penadés, Javier del Pino-Montes, Julio Sanjuán & Celso Arango. (2017) Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Revista de Psiquiatría y Salud Mental 10:1, pages 4-20.
Crossref
Crossref
Ayse Sakalli Kani, Ann K. Shinn, Kathryn E. Lewandowski & Dost Öngür. (2017) Converging effects of diverse treatment modalities on frontal cortex in schizophrenia: A review of longitudinal functional magnetic resonance imaging studies. Journal of Psychiatric Research 84, pages 256-276.
Crossref
Crossref
Tongeji E. Tungaraza. (2016) Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. Therapeutic Advances in Psychopharmacology 6:5, pages 335-342.
Crossref
Crossref
G. Mezquida, R. Penadés, B. Cabrera, G. Savulich, A. Lobo, A. González-Pinto, M.J. Penzol, I. Corripio, E. Fernandez-Egea, P. Gassó, M.J. Cuesta & M. Bernardo. (2020)
Association of the
brain-derived neurotrophic factor
Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders
. European Psychiatry 38, pages 61-69.
Crossref
Crossref
Gary Remington, George Foussias, Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee & Margaret Hahn. (2016) Treating Negative Symptoms in Schizophrenia: an Update. Current Treatment Options in Psychiatry 3:2, pages 133-150.
Crossref
Crossref
Marjorie Garvey, Shelli Avenevoli & Kathleen Anderson. (2016) The National Institute of Mental Health Research Domain Criteria and Clinical Research in Child and Adolescent Psychiatry. Journal of the American Academy of Child & Adolescent Psychiatry 55:2, pages 93-98.
Crossref
Crossref
Yuki Aoyama, Kazuya Toriumi, Akihiro Mouri, Tomoya Hattori, Eriko Ueda, Akane Shimato, Nami Sakakibara, Yuka Soh, Takayoshi Mamiya, Taku Nagai, Hyoung-Chun Kim, Masayuki Hiramatsu, Toshitaka Nabeshima & Kiyofumi Yamada. (2015) Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex. Neuropsychopharmacology 41:2, pages 578-589.
Crossref
Crossref
Pongsatorn Paholpak & Mario F. Mendez. 2016. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry
327
344
.
Josep Maria Haro, Carlo Altamura, Ricardo Corral, Helio Elkis, Jonathan Evans, Ashok Malla, Marie-Odile Krebs, Mathias Zink, Corrado Bernasconi, Justine Lalonde & Anna-Lena Nordstroem. (2015) Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. Schizophrenia Research 169:1-3, pages 234-240.
Crossref
Crossref
Siok Ching Chia, Jeyakumar Henry, Yee Ming Mok, William G. Honer & Kang Sim. (2015) Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence. Journal of Neural Transmission 122:12, pages 1721-1732.
Crossref
Crossref
Norio Sugawara, Masamichi Ishioka, Shoko Tsuchimine, Koji Tsuruga, Yasushi Sato, Hanako Furukori, Shuhei Kudo, Tetsu Tomita, Taku Nakagami & Norio Yasui-Furukori. (2015) Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. PLOS ONE 10:11, pages e0143356.
Crossref
Crossref
Christopher J. Heath, Timothy J. Bussey & Lisa M. Saksida. (2015) Motivational assessment of mice using the touchscreen operant testing system: effects of dopaminergic drugs. Psychopharmacology 232:21-22, pages 4043-4057.
Crossref
Crossref
Daniel Bertrand, Chih-Hung L. Lee, Dorothy Flood, Fabrice Marger & Diana Donnelly-Roberts. (2015)
Therapeutic Potential of
α
7 Nicotinic Acetylcholine Receptors
. Pharmacological Reviews 67:4, pages 1025-1073.
Crossref
Crossref
Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo & Niufan Gu. (2015) Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. Journal of Psychiatric Research 69, pages 102-109.
Crossref
Crossref
Antonio M. Persico, Celso Arango, Jan K. Buitelaar, Christoph U. Correll, Jeffrey C. Glennon, Pieter J. Hoekstra, Carmen Moreno, Benedetto Vitiello, Jacob Vorstman & Alessandro Zuddas. (2015) Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. European Neuropsychopharmacology 25:10, pages 1513-1531.
Crossref
Crossref
Monika Szkultecka-Dębek, Jacek Walczak, Joanna Augustyńska, Katarzyna Miernik, Jarosław Stelmachowski, Izabela Pieniążek, Grzegorz Obrzut, Angelika Pogroszewska, Gabrijela Paulić, Marić Damir, Siniša Antolić, Rok Tavčar, Andra Indrikson, Kaire Aadamsoo, Slobodan Jankovic, Attila J Pulay, József Rimay, Márton Varga, Ivana Sulkova & Petra Veržun. (2015) Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review. Clinical Practice & Epidemiology in Mental Health 11:1, pages 158-165.
Crossref
Crossref
Stefan Westermann, Marialuisa Cavelti, Eva Heibach & Franz Caspar. (2015) Motive-oriented therapeutic relationship building for patients diagnosed with schizophrenia. Frontiers in Psychology 6.
Crossref
Crossref
Greg C. Bristow, John A. Bostrom, Vahram Haroutunian & Monsheel S. Sodhi. (2015) Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophrenia Research 167:1-3, pages 57-63.
Crossref
Crossref
Deanna L. Kelly, Kelli M. Sullivan, Joseph P. McEvoy, Robert P. McMahon, Heidi J. Wehring, James M. Gold, Fang Liu, Dale Warfel, Gopal Vyas, Charles M. Richardson, Bernard A. Fischer, William R. Keller, Maju Mathew Koola, Stephanie M. Feldman, Jessica C. Russ, Richard S. E. Keefe, Jennifer Osing, Leeka Hubzin, Sharon August, Trina M. Walker & Robert W. Buchanan. (2015) Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. Journal of Clinical Psychopharmacology 35:4, pages 374-381.
Crossref
Crossref
Meng-Lin Li, Xi-Quan Hu, Feng Li & Wen-Jun Gao. (2015) Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 60, pages 66-76.
Crossref
Crossref
R. Jørgensen, R.W. Licht, P.H. Lysaker, P. Munk-Jørgensen, K.D. Buck, S.O.W. Jensen, L. Hansson & V. Zoffmann. (2020) Effects on cognitive and clinical insight with the use of Guided Self-Determination in outpatients with schizophrenia: A randomized open trial. European Psychiatry 30:5, pages 655-663.
Crossref
Crossref
Chittaranjan Andrade, Steve Kisely, Ingrid Monteiro & Sanjay Rao. (2015) Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research 60, pages 14-21.
Crossref
Crossref
Błażej Misiak, Dorota Frydecka, Łukasz Łaczmański, Ryszard Ślęzak & Andrzej Kiejna. (2014) Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. European Journal of Clinical Pharmacology 70:12, pages 1433-1441.
Crossref
Crossref